NCT02531516 2026-03-19
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Aragon Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Alessa Therapeutics Inc.
M.D. Anderson Cancer Center
NRG Oncology
Big Ten Cancer Research Consortium
RTOG Foundation, Inc.
Brigham and Women's Hospital
Medicine Invention Design, Inc
Memorial Sloan Kettering Cancer Center
University of Chicago
Radiation Therapy Oncology Group
City of Hope Medical Center
Stanford University